TCTR20220301002已完成不适用
ong term immunogenicity of BNT162b2 vaccination and attitudes toward COVID-19 booster vaccines in Thai children
Ratchadapisek Research Funds0 个研究点目标入组 240 人开始时间: 2022年3月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 240
研究概览
简要总结
A booster dose of BNT162b2 elicits high immunogenicity against the Omicron variant. Motivation for receiving booster doses is to reduce risk of infection
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 5 Years 至 18 Years（—）
- 性别
- All
入选标准
- •1. Participants must age 5 to <18 years old on the day of first dose vaccination, 2. Participants must be completed second dose of BNT162b2 vaccine for 6 months at the time of data collection, 3.Participants must be in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs), and the clinical judgment of the investigator, 4.Participants and parent(s) must be able to communicate effectively with study personnel and considered reliable, willing, and cooperative in terms of compliance with the protocol requirements, 5.Participants and/or parent(s) or legally authorized representative(s) must sign a written informed consent form, including any required privacy authorization form, prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements
排除标准
- •1. Participants with previous documented SARS-CoV-2 infection, 2. Receipt of immunoglobulins or blood products between the day of first vaccination and blood collection, 3.Receipt of any other vaccines within 14 days (for inactivated vaccines except influenza vaccine) or 28 days (for lived vaccines) prior to blood collection, 4. Use of any medications that may be associated with impaired immune responsiveness or with immunosuppression.
研究者
相似试验
已完成
2 期
Immunogenicity after booster dose with mRNA BNT162b2 among elderly or adult with underlying diseases who had received AZD1222 using standard versus low dose via intramuscular route (COVID-19)Prevention of COVID-19 with booster SARS-CoV-2 vaccine using BNT162b2, comparing standard dose vs low dose, in elderly or adult with underlying diseases.SARS-CoV-2, mRNA vaccine, ChAdOx1 nCoV-19 vaccine, Immunogenicity, ReactogenicityTCTR20211027002ational Vaccine Institute100
已完成
1 期
Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 boosterThe immunogenicity and safety of BNT162b2 as a booster dose following fully immunized with inactivated vaccine in Thai children aged 5-11 years.SARS-CoV-2, Inactivated SARS-CoV-2 vaccine, BNT162b2, Children, BoosterTCTR20220330001ational Vaccine Institute60
已完成
不适用
Covid-19 Vaccine Response in Elderly SubjectsCovid19 VaccineNCT04760704University Hospital, Lille264
已完成
2 期
Safety and Immunogenicity of SARS-CoV-2 mRNA vaccine platform in Thai children aged 5-11 yearsPrevention of COVID-19 with SARS-CoV-2 mRNA vaccine platform, comparing standard and prolong interval, in healthy Thai childrenSARS-CoV-2, mRNA vaccine, COVID-19 vaccine, Children, Immunogenicity, ReactogenicityTCTR20220125002ational Vaccine Institute344
尚未招募
不适用
Immunogenicity of 2 dose regimen of BNT162b2 mRNA vaccine in Thai children aged 6 months to 4 years following COVID 19 (COVID-19)Prevention of COVID-19 with 2-dose mRNA vaccine among healthy Children 6 month to 4 years who had COVID-19 infectionSARS-CoV-2, mRNA vaccine, Infant, Children, Immunogenicity, ReactogenicityTCTR20221018008Ratchadaphisek Sompoch Research Fund80